IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver

Immunology and Cell Biology

Volumn 90, Issue 6, 2012, Pages 611-619

  Xiang, Xiaogang ^a,b   Gui, Honglian ^a,b   King, Nicholas Jc ^b   Cole, Louise ^a   Wang, Hui ^a   Xie, Qing ^a   Bao, Shisan ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

IL 17; IL 22; inflammation; liver cirrhosis; non ELR CXC chemokines

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGININE; CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMIC ACID; GLUTAMYLLEUCYLARGININE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; LEUCINE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIVER CIRRHOSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN MOTIF; STATISTICAL SIGNIFICANCE;

ADULT; ALANINE TRANSAMINASE; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKINS; KUPFFER CELLS; LIVER; LIVER CIRRHOSIS; MALE;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84863726312     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.79     Document Type: Article

References (38)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
3. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27: 152-160.
4. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS et al. The role of virusspecific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
5. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007; 85: 16-23.
6. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
7. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl JMed 2009; 361: 888-898.
8. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10: 864-871.
9. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-3585.
10. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010; 32: 17-31.
11. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-659.
12. Pan H, Hong F, Radaeva S, Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 2004; 1: 43-49.
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242.
14. Muller M, Carter S, Hofer MJ, Campbell IL. The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity-a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36: 368-387.
15. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-1450.
16. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52: 330-339.
17. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9: 639-651.
18. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson Jr. et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 1230-1238.
19. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000; 46: 260-269.
20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
21. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-433.
22. Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SML et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal ALT. J Viral Hep 2010; 17: 44-50.
23. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-415.
24. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
25. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39: 1332-1342.
26. Ren X, Colletti LM. IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol Gastrointest Liver Physiol 2009; 298: G74-80.
27. O'Quinn DB, Palmer MT, Lee YK, Weaver CT. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99: 115-163.
28. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G et al. Involvement of Th17 and Th1 effector responses in patients with hepatitis B. J Clin Immunol 2010; 30: 546-555.
29. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173: 310-317.
30. Hokeness KL, Deweerd ES, Munks MW, Lewis CA, Gladue RP, Salazar-Mather TP. CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. J Virol 2007; 81: 1241-1250.
31. Bone-Larson CL, Hogaboam CM, Evanhoff H, Strieter RM, Kunkel SL. IFN-gammainducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J Immunol 2001; 167: 7077-7083.
32. Muse M, Kane JA, Carr DJ, Farber JM, Lane TE. Insertion of the CXC chemokine ligand 9 (CXCL9) into the mouse hepatitis virus genome results in protection from viralinduced encephalitis and hepatitis. Virology 2008; 382: 132-144.
33. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137: 309-319, 19 e1-3.
34. Hyodo N, Tajimi M, Ugajin T, Nakamura I, Imawari M. Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. Hepatol Res 2003; 27: 109-116.
35. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 2: 92-100.
36. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010; 34: 1-6.
37. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
38. Patel S, Chung S, White J, Shisan Bao, Celermajer D. The ''atheroprotective'' mediators apolipoproteinA-I and Foxp3 are over-abundant in unstable carotid plaques. Int J Cardiol 2010; 145: 183-187.